Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
12.7M
-
Shares change
-
+2.36M
-
Total reported value, excl. options
-
$288M
-
Value change
-
+$54.8M
-
Number of buys
-
36
-
Number of sells
-
-25
-
Price
-
$22.75
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q3 2019
71 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2019.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.7M shares
of 80M outstanding shares and own 15.93% of the company stock.
Largest 10 shareholders include venBio Partners LLC (3.95M shares), JANUS HENDERSON GROUP PLC (2.03M shares), Redmile Group, LLC (1.16M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (749K shares), Cormorant Asset Management, LP (741K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (525K shares), ALKEON CAPITAL MANAGEMENT LLC (503K shares), BOXER CAPITAL, LLC (482K shares), BVF INC/IL (472K shares), and BlackRock Inc. (308K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.